The best enterprise use case for generative AI right now is standing in for unavailable experts under deadline pressure. With my team on holiday and a client contract due in 24 hours, Claude drafted and refined the entire document with the depth of a team of local specialists. GenAI is not hype; on days like that it is business critical.
It is summer in the Nordic countries and my team are all on vacation and difficult to reach. An opportunity to work with a new client in the Americas came with a 24 hour turnaround time. Since no on was available, I used my go to GenAI, Anthropic’s Claude 3.5 Sonnet, to replace each of the individuals of my team and it worked!
As I wrote the contract, I separated each part of writing the contract to Claude so that Claude had a complete overview of the whole contract and also understood what each section of the contract was written and why changes were made. Working with Claude was like having endless resources of professionals who had local business experience to help me to craft a winning professional contract with specific references and clauses that made our offer stand out and ability to work internationally be self evident.
Another realization was the incredible speed that Claude worked at. Detailed answers were provided in seconds with example of optimized contractual text, suggestions of new sections for the contract and why, and always asking if I wanted to look into other areas I had not thought of. Claude made suggestions that I did not choose to use but it gave more confidence of the quality for the final contract.
Best use case for generative AI
Can GenAI at times replace people? Yes. Would it be better to supplement the experts you already have on your team? Absolutely but when they are not available you can using GenAI (Claude) produce excellent results in an incredibly short period of time.
Contract has been sent and now I can smile in the sun knowing that GenAI is not hype. It’s business critical!
Thomas Anglero is a Strategic AI Advisor, keynote speaker and author of Intro to Artificial Intelligence. He has delivered over 450 keynotes across 30 countries for organisations including IBM, the WHO, the World Government Summit and the European Commission. He founded the IBM Watson AI Lab for Cancer at the Oslo Cancer Cluster and closed over $500 million in enterprise transformation deals as CTO and Chief Innovation Officer at Cognizant.